MW108 is an active site targeted, CNS-active, p38αMAPK inhibitor. It acts by ameliorating beta-amyloid induced synaptic and cognitive dysfunction and preventing early memory loss in Alzheimer's disease. References: Kheiri G, Dolatshahi M, Rahmani F, Rezaei N. Role of p38/MAPKs in Alzheimer's disease: implications for amyloid beta toxicity targeted therapy. Rev Neurosci. 2018 May 28. pii: /j/revneuro.ahead-of-print/revneuro-2018-0008/revneuro-2018-0008.xml. doi: 10.1515/revneuro-2018-0008. [Epub ahead of print] PubMed PMID: 29804103.

纯度：≥98%

CAS：1454658-89-9